Home / Companies / Glenmark Pharmaceuticals Limited / 7 Nov 2023
Glenmark Pharmaceuticals Limited: meeting of 7 Nov 2023
Votes reported on Form N-PX, item by item
34 Form N-PX filers reported votes at the Glenmark Pharmaceuticals Limited meeting of 7 Nov 2023. Their records fall into 2 items below, in ballot order: management items first, then proposals from security holders. Each bar shows how the reporting filers split; it is not the result of the meeting.
foragainstabstain, withhold or otheramber tick: the portion cast against management
Items
EXTRAORDINARY TRANSACTIONSIssuer
EXTRAORDINARY TRANSACTIONS: management items
Management items in this category are shown together; filers word and number them differently.
45 vote records from 34 filers. 0 of the 34 filers that marked the item either way voted against management.
One filer reported a share count too large to be the holding described. That figure is left out of the share split below; the count of filers includes it. How that is decided
OTHERIssuer
OTHER: management items
Management items in this category are shown together; filers word and number them differently.
4 vote records from 4 filers. No filer marked a management recommendation, so no against-management figure is reported. 4 filers reported this item without a management mark.
How the largest families voted
None of the families tracked on this site reported a position on these items.
Questions
How did large funds vote at the Glenmark Pharmaceuticals Limited meeting?
34 Form N-PX filers reported votes at the meeting of 7 Nov 2023. The family table lists each of the largest families item by item.
Is this the meeting result?
No. These are the votes of funds and managers that file Form N-PX, counted by filer and by the shares they reported. The certified result, which includes every shareholder, is reported by Glenmark Pharmaceuticals Limited on Form 8-K.
Why are director elections shown as counts only?
Director records name the nominee. This site does not publish pages or rows about individuals, so for director elections it keeps the number of nominees and the split of votes and discards the wording.
Every meeting on file for Glenmark Pharmaceuticals Limited
Provenance: SEC EDGAR, Form N-PX and N-PX/A filings listing Glenmark Pharmaceuticals Limited with a meeting date within three days of 7 Nov 2023. Proposal titles are the most common wording among filers and are replaced by the SEC category where a wording could name a person. Not verified by the SEC. Filings read through 23 Sep 2026.